Future Science Group (FSG) today announced the publication of a new article in Future Science OA synthesizing current data on sarcopenic obesity, and looking to highlight the need for public health strategies for prevention and treatment.
Sarcopenic obesity is the combination of low muscle mass and high fat mass. Tending to be more common in older adults owing to natural changes associated with aging, sarcopenic obesity has the potential to become of increasing public health concern. In addition, evidence suggests that older adults with sarcopenic obesity have increased risks of mobility issues, metabolic disease, hypertension, cardiovascular disease and mortality. However, limited data in terms of prevention and treatment are available, largely owing to differences in definition and assessment. The new article aimed to synthesize current data to improve our understanding of this phenomenon, and look towards effective health strategies.
"Although the adverse health impact of sarcopenic obesity in aging populations is rapidly growing in most developed countries, there is very little evidence on sarcopenic obesity. Physical activity has been recognized as a key lifestyle factor to prevent and delay muscle loss and obesity with aging; however, few data are currently available on the effects of physical activity on sarcopenic obesity in older adults," explained Duck-Chul Lee, first author and Assistant Professor at Iowa State University, USA. "This review highlights the importance of the urgent investigation and development of universal definition, assessment, and diagnosis of sarcopenia and sarcopenic obesity for both research studies and clinical practice."
With current studies suggesting the potential benefits of physical activity, fitness and resistance exercise on the prevention and treatment of sarcopenic obesity in older adults, Francesca Lake, Managing Editor of Future Science OA, notes: "Given its rapidly increasing health impact, it is clear we need to identify effective public health strategies and programs to both treat and prevent sarcopenic obesity. In order to do this, we need to standardize its definition and assessment. We hope this article will help move research forward in this arena."
###
The article is available free to read at: http://www.future-science.com/doi/full/10.4155/fsoa-2016-0028.
About Future Science OA
Launched in March 2015, Future Science OA is the inaugural gold open access journal from Future Science Group. It publishes articles covering research of application to human health, and utilizes a CC-BY license. Future Science OA embraces the importance of publishing all good-quality research with the potential to further the progress of medical science. Negative and early-phase research will be considered. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.futuresciencegroup.com
Journal
Future Science OA